The Numbers Were Great. The Market Didn't Care.

Abivax's experimental drug obefazimod just delivered a 40% placebo-adjusted clinical remission rate in a 48-week Phase 3 maintenance trial. Patients with ulcerative colitis — a miserable, chronic bowel disease — went into remission at rates that outpace most existing treatments.

According to FierceBiotech, the closest competitor is AbbVie's Rinvoq, which achieved a 39% placebo-adjusted remission rate. Pfizer's Velsipity checks in at 32%. Obefazimod beat them both. Abivax achieved this in a harder-to-treat population: about 40% of trial patients had already failed advanced therapies before enrolling.

Leerink Partners analysts called the remission rates a "best-case" outcome. Citizens JMP Securities analyst Jason Butler said efficacy exceeded his expectations, according to Ground News. The drug met all primary and key secondary endpoints. By any clinical measure, this is a win.

Yet the stock lost 40%.

Eight Cancer Cases. That's What Wall Street Saw.

The ABTECT maintenance trial data contained a table nobody wanted to see: eight malignancy cases, all among patients taking the higher 50 mg dose.

According to ZeroHedge, Goldman analyst Esah Hayat flagged that investors were laser-focused on those cancer cases, not the efficacy wins. The breakdown, per CNBC: one prostate cancer, one breast cancer, one colonic dysplasia, and four skin cancers. Abivax said investigators deemed all of them unrelated to the drug. Two of the four skin cancer patients had a prior medical history of skin cancer. No organ-specific clustering was observed.

Abivax CEO Marc de Garidel defended the safety profile publicly, maintaining the cancers were unrelated to treatment, according to Ground News. The company's own data monitoring committees did NOT flag a new safety signal.

What Abivax Is Saying — And What the Analysts Think

Abivax brought in Dr. David Rubin, director of the inflammatory bowel disease center at the University of Chicago Medicine, to contextualize the data. Rubin said the malignancy rates align with background cancer rates seen in ulcerative colitis patients generally — a point backed up by Abivax management on their investor call, per ZeroHedge.

Rinvoq carries a boxed warning — the FDA's most serious safety label — covering five warnings including higher all-cause mortality, according to FierceBiotech. Obefazimod showed placebo-like infection rates and fewer treatment-related discontinuations than the placebo arm. On almost every other safety metric, the drug looks clean.

But a Jefferies analyst cited by CNBC wasn't convinced. The analyst downgraded Abivax to Hold from Buy and called the cancer signal an overhang that "doesn't seem like an easily dismissed" problem, especially with no other major data catalysts expected for at least a year.

The $17.5 Billion Question

This wasn't just a drug data event. It was a M&A event.

According to FierceBiotech, AstraZeneca and Eli Lilly were both reportedly circling Abivax, with a potential deal valued at up to $18 billion. Ground News cited a rumored $17.5 billion bid from Eli Lilly specifically. Abivax had been waiting on the 48-week maintenance data — essentially this dataset — before entertaining serious deal talks.

The cancer cases made Big Pharma's legal and regulatory departments very nervous. ZeroHedge's Goldman sourcing put it bluntly: pharma business development teams are now unlikely to absorb that regulatory risk. A blockbuster takeout is no longer the obvious next chapter.

Abivax stock had run nearly 1,700% in 2025, almost entirely on M&A speculation and the initial Phase 3 efficacy shock. A lot of that gain was priced-in buyout premium — and that premium just took a direct hit.

What the Media Is Getting Wrong

Most outlets are framing this as a binary: great drug, scary cancer signal, stock crashes, story over.

ZeroHedge raised an interesting analytical question: could this become a "Fenebrutinib-like situation" where the market panics on headline safety data, investigators later explain the cases away at a formal presentation, doctors come out in support, and the stock re-rates upward?

FierceBiotech did the best job of actual drug-to-drug comparison work, noting that Rinvoq's boxed warning dwarfs anything seen in the obefazimod data. That context is almost entirely absent from CNBC's coverage, which leaned heavily on the fear angle.

CNBC also buried the M&A dimension. That's where the real market movement lies.

What This Means for Real People

About 3 million Americans live with inflammatory bowel disease. Ulcerative colitis specifically has limited treatment options, and the drugs that exist — including JAK inhibitors like Rinvoq — carry serious risks including cancer and cardiovascular events.

Obefazimod, if it clears regulatory review, could be a genuinely better option for a lot of patients. The efficacy numbers are real. The cancer cases, based on current evidence, appear to reflect background disease rates — not drug toxicity.

Abivax says it plans to file for regulatory approval by year-end. A Crohn's disease trial readout is expected in mid-2027, per Ground News.

The drug may still get approved. The science may vindicate Abivax. But today, Wall Street made its call.